May 29, 2023
Our team members Dr. Lior Shaltiel, PhD, CEO, Dr. Ina Sarel, Head of CMC Quality and regulation, and Dr. Lyora Aharonov, Director of Research and Developments, will represent NurExone Biologic during the conference. Read More >>>
Prof. Levenberg presented NurExone’s recent developments and innovative technology to the intrigued crowd, while showing the exciting scientific milestones ahead! Read More >>>
This is a remarkable honor, as the College of Fellows is comprised of only the top two percent of the most accomplished and distinguished professors, researchers, innovators, and entrepreneurs in the fields of #medical and #biologicalengineering. Read More >>>
“The Company is successfully achieving key milestones for our investigational ExoPTEN drug and, in parallel, developing an exosome therapy platform that can be widely used by the medical industry to address many other illnesses,” Dr. Lior Shaltiel, CEO of NurExone. “We believe that the hybrid product-platform model will drive revenue
TORONTO and TEL AVIV, Israel, May 16, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone“) (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that the Company has received an issue notification from the United States
Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 12, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC (“Litchfield”) to
Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 8, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone“), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options (“Options“) and